C. Ola Landgren: Expanding Myeloma Program at Sylvester Comprehensive Cancer Center – New Faculty Position Available
C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared the following insightful post on LinkedIn:
“New opportunity: We are expanding our innovative and highly successful myeloma program in beautiful Miami! We are looking to recruit a Full-time faculty myeloma physician at the Division of Myeloma and Sylvester Myeloma Institute, University of Miami, Sylvester Comprehensive Cancer Center, the only National Cancer Institute (NCI) designated cancer center in South Florida.
We are looking for an academically interested physician with a focus on multiple myeloma and related conditions. Apply here.
The perfect candidate for this new job (MD or MD/PhD) could either be (i) a Clinical Investigator (develop and lead clinical trials), or (ii) a Laboratory-Based Investigator (develop and lead either wet-lab- or dry-lab-research). Either way, we are looking for a physician with a focus on cutting-edge clinical care, modern treatment strategies, teamwork, and an interest in drug development and novel ideas. For a Clinical Investigator, we will support the development of a strong clinical trials portfolio within the Myeloma Institute, and for a Laboratory-Based Investigator, we will support the development of a strong laboratory-based research program, also within the Myeloma Institute. There are lots of opportunities here in Miami!
Sylvester Comprehensive Cancer Center’s catchment area is over 6.2 million people. The Division of Myeloma and Myeloma Research Institute provides world-class care to a large number of myeloma patients in Miami, across the U.S., and internationally. Our clinical trials portfolio is extensive; focusing primarily on Phase 1 and Phase 2 clinical trials, we bring all the latest anti-myeloma drugs to our patients. Our world-class computational discovery research laboratory continues to deliver cutting edge innovative research geared toward computational oncology.
We recently opened a brand new laboratory of epigenetics in myeloma, and we are rapidly expanding our functional wet laboratory-based research. Sylvester Myeloma Institute covers all the bases – preclinical (wet lab), clinical (trials) and computational (dry lab) science with focus on multiple myeloma and related conditions. We have a strong network of collaborators including other key centers worldwide.”
More posts featuring C. Ola Landgren.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023